Gene · 9475
Papers3,801
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,801
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease. | Expert Opin Investig Drugs | 2025 | 40407836 | PubTator, text mining | PubMed |
| Inhibition of Rho-Associated Kinases ROCK1 and ROCK2 as a Therapeutic Strategy to Reactivate the Repressed FXN Gene in Friedreich Ataxia. | J Neurosci | 2025 | 40404357 | PubTator, text mining | PubMed |
| OSBPL2 deficiency inhibits Rho/ROCK2/p-ERM signaling and impairs actin cytoskeletal regulation in auditory cells. | J Biomed Res | 2025 | 40391522 | PubTator, text mining | PubMed |
| The effects of interleukin-21 in the biology of transplant rejection. | Front Immunol | 2025 | 40376002 | PubTator, text mining | PubMed |
| Design, optimization, and ADMET evaluation of S11a-0000168202: A promising LIMK1 inhibitor for gastric cancer treatment. | PLoS One | 2025 | 40367093 | PubTator, text mining | PubMed |
| Discovery of ROCK2 inhibitors through computational screening of ZINC database: Integrating pharmacophore modeling, molecular docking, and MD simulations. | PLoS One | 2025 | 40359277 | PubTator, text mining | PubMed |
| Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies. | Transplant Cell Ther | 2025 | 40318736 | PubTator, text mining | PubMed |
| Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study. | Blood Adv | 2025 | 40311075 | PubTator, text mining | PubMed |
| Loss of DRD5P2 in hypoxia attenuates Rock2 degradation to promote EMT and gastric cancer metastasis. | Biochim Biophys Acta Mol Basis Dis | 2025 | 40280198 | PubTator, text mining | PubMed |
| The Groebke-Blackburn-Bienaymé (GBB) reaction: A powerful tool for generating diverse heterocyclic scaffold libraries in anticancer drug discovery. | Eur J Med Chem | 2025 | 40253794 | PubTator, text mining | PubMed |
| Drug and siRNA screens identify ROCK2 as a therapeutic target for ciliopathies. | Commun Med (Lond) | 2025 | 40253509 | PubTator, text mining | PubMed |
Exploring the mechanism of triptolide inhibiting the motility of fibroblast-like synoviocytes in rheumatoid arthritis via RhoA/Rho-associated kinase axis, based on network pharmacology, molecular docking and molecular dynamics simulations. | Front Pharmacol | 2025 | 40248103 | PubTator, text mining | PubMed |
| Neural network analysis as a novel skin outcome in a trial of belumosudil in patients with systemic sclerosis. | Arthritis Res Ther | 2025 | 40217251 | PubTator, text mining | PubMed |
| ROCK2 Downregulation in Pediatric Medulloblastoma Increases Migration and Predicts the Involvement of SHH Non-canonical Signaling. | Yale J Biol Med | 2025 | 40165809 | PubTator, text mining | PubMed |
| In Vitro and Clinical Evaluations of UGT1A1-, P-gp-, OATP1B1-, and BCRP-Mediated Drug-Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor. | J Clin Pharmacol | 2025 | 40145677 | PubTator, text mining | PubMed |
| Model-informed drug development of novel ROCK2 inhibitor TDI01: population pharmacokinetic study and simulation. | Front Pharmacol | 2025 | 40103594 | PubTator, text mining | PubMed |
| The role of MicroRNAs in mesenchymal stem cell differentiation into vascular smooth muscle cells. | Cell Div | 2025 | 40055797 | PubTator, text mining | PubMed |
| Diagnostic value of ROCK2 protein in immune checkpoint inhibitors-associated myocarditis. | Int J Cardiol | 2025 | 40037484 | PubTator, text mining | PubMed |
| [Pharmacological and clinical profiles of belumosudil mesylate (REZUROCK® Tablets), a selective inhibitor of ROCK2]. | Nihon Yakurigaku Zasshi | 2025 | 40024700 | PubTator, text mining | PubMed |
| Hsa_circ_0125356 promotes gemcitabine resistance by modulating WNT canonical and non-canonical pathways via miR-582-5p/FGF9 axis in non-small cell lung cancer. | Mol Cancer | 2025 | 40011917 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9475/papers?page=9